论文部分内容阅读
利用与肿瘤增殖相关的调控基因及细胞因子治疗恶性肿瘤是现代肿瘤治疗的又一发展。本文采用基因工程重组白介素2(IL-2)诱导人外周血淋巴因子激活的杀伤细胞(LAK细胞),配合化疗药物综合介入式局部应用治疗晚期肿瘤。结果显示:采用IL-2+LAK细胞腔内局部灌注、配合肿瘤靶血管介入化疗及小剂量1L—2肌肉注射,对消除癌性胸,腹水效果显著,有效率达100％,而介入综合治疗组与对照组比较显示前者的总缓解率提
The use of regulatory genes and cytokines associated with tumor proliferation to treat malignant tumors is yet another development in modern cancer therapy. In this study, we used genetically engineered recombinant interleukin 2 (IL-2) to induce human peripheral lymphokine-activated killer cells (LAK cells), combined with chemotherapeutic drugs in combination with topical application in the treatment of advanced tumors. The results showed that the use of IL-2 + LAK intracellular local perfusion, combined with tumor target vessel intervention chemotherapy and low-dose 1L-2 intramuscular injection was effective in eliminating cancerous thoracic and ascites, with an effective rate of 100%, and interventional comprehensive treatment. The comparison between the group and the control group shows the total remission rate of the former